HLA-G class I gene expression in normal and malignant hematopoietic cells, Human Immunology, vol.59, issue.8, pp.524-528, 1998. ,
DOI : 10.1016/S0198-8859(98)00041-X
Not All Polyriboinosinic-polyribocytidylic Acids (Poly I:C) are Equivalent for Inducing Maturation of Dendritic Cells, Journal of Immunotherapy, vol.32, issue.4, pp.353-362, 2009. ,
DOI : 10.1097/CJI.0b013e31819d29bf
URL : https://hal.archives-ouvertes.fr/inserm-00373586
HLA-G remains a mystery, Trends in Immunology, vol.22, issue.10, pp.548-552, 2001. ,
DOI : 10.1016/S1471-4906(01)02031-2
Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies, Clinical Cancer Research, vol.14, issue.10, pp.3044-3051, 2008. ,
DOI : 10.1158/1078-0432.CCR-07-4079
Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies, 2009. ,
Beyond the increasing complexity of the immunomodulatory HLA-G molecule, Blood, vol.111, issue.10, pp.4862-4870, 2008. ,
DOI : 10.1182/blood-2007-12-127662
Glioblastomas Induce T-Lymphocyte Death by Two Distinct Pathways Involving Gangliosides and CD70, Cancer Research, vol.65, issue.12, pp.5428-5438, 2005. ,
DOI : 10.1158/0008-5472.CAN-04-4395
HLA-G in melanoma: can the current controversies be solved?, Seminars in Cancer Biology, vol.13, issue.5, pp.361-369, 2003. ,
DOI : 10.1016/S1044-579X(03)00027-0
Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia, J. Immunol, vol.148, pp.1404-1410, 1992. ,
Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients??? sera by HPLC and is inducible by IFN-??, Leukemia Research, vol.33, issue.3, pp.490-494, 2009. ,
DOI : 10.1016/j.leukres.2008.06.014
HLA-G Expression by Tumors, American Journal of Reproductive Immunology, vol.45, issue.2, 2001. ,
DOI : 10.1111/j.8755-8920.2001.450207.x
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat. Med, vol.8, pp.793-800, 2002. ,
Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses, Cancer Res, vol.66, pp.5883-5891, 2006. ,
TGF-?? and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells, Brain, vol.129, issue.9, pp.2416-2425, 2006. ,
DOI : 10.1093/brain/awl205
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J. Exp. Med, vol.192, pp.1027-1034, 2000. ,
Transforming growth factor-beta in T-cell biology, Nat. Rev, 2002. ,
Inhibition of indoleamine 2,3-dioxygenase activity in IFN-?? stimulated astroglioma cells decreases intracellular NAD levels, Biochemical Pharmacology, vol.66, issue.6, pp.1033-1036, 2003. ,
DOI : 10.1016/S0006-2952(03)00464-7
Fas Ligand Expression in Glioblastoma Cell Lines and Primary Astrocytic Brain Tumors, Brain Pathology, vol.94, issue.3, pp.863-869, 1997. ,
DOI : 10.1093/intimm/6.10.1567
THE B7 FAMILY REVISITED, Annual Review of Immunology, vol.23, issue.1, pp.515-548, 2005. ,
DOI : 10.1146/annurev.immunol.23.021704.115611
Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape, Immunological Reviews, vol.176, issue.1, pp.206-221, 2008. ,
DOI : 10.1093/carcin/16.2.399
A class I antigen, HLA-G, expressed in human trophoblasts, Science, vol.248, issue.4952, pp.220-223, 1990. ,
DOI : 10.1126/science.2326636
Processing of Immunosuppressive Pro-TGF-??1,2 by Human Glioblastoma Cells Involves Cytoplasmic and Secreted Furin-Like Proteases, The Journal of Immunology, vol.166, issue.12, pp.7238-7243, 2001. ,
DOI : 10.4049/jimmunol.166.12.7238
Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment, Clinical Cancer Research, vol.11, issue.15, pp.5515-5525, 2005. ,
DOI : 10.1158/1078-0432.CCR-05-0464
Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy, Journal of Neurosurgery, vol.111, issue.2, 2009. ,
DOI : 10.3171/2008.10.JNS081141
Indoleamine 2,3-dioxygenase and tumor-induced tolerance, Journal of Clinical Investigation, vol.117, issue.5, 2007. ,
DOI : 10.1172/JCI31178
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1857253
Prevention of allogeneic fetal rejection by tryptophan catabolism, Science, vol.281, pp.1191-1193, 1998. ,
The Fas death factor, Science, vol.267, issue.5203, pp.1449-1456, 1995. ,
DOI : 10.1126/science.7533326
Expression of tumour necrosis factor-alpha, beta and interferon-gamma genes within human neuroglial tumour cells and brain specimens, 1994. ,
Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain, Clin. Cancer Res, vol.8, pp.2851-2855, 2002. ,
Role of transforming growth factor beta in cancer, Journal of Cellular Physiology, vol.25, issue.18, pp.153-168, 2001. ,
DOI : 10.1002/1097-4652(200002)186:2<153::AID-JCP1016>3.0.CO;2-J
The effects of interferon-?? on the central nervous system, Molecular Neurobiology, vol.8, issue.1-2, pp.19-35, 1997. ,
DOI : 10.1007/BF02740619
Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of Tcell proliferation in human epithelial ovarian cancer, Cancer Res, vol.69, pp.5498-5504, 2009. ,
Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?, J. Clin. Invest, vol.99, pp.1173-1178, 1997. ,
Overcoming tumor antigen anergy in human malignancies using the novel indeolamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT), J. Clin. Oncol (Meeting Abstracts, vol.27, p.3004, 2009. ,
Protein Expression of Fas, Fas Ligand, Bcl-2 and TGF??2 and Correlation with Survival in Initial and Recurrent Human Gliomas, Journal of Neuro-Oncology, vol.67, issue.1/2, pp.29-39, 2004. ,
DOI : 10.1023/B:NEON.0000021739.34343.75
European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, Lancet Oncol, vol.10, pp.459-466, 2009. ,
Microglia and macrophages as innate producers of interferon-gamma in the brain following infection with Toxoplasma gondii, International Journal for Parasitology, vol.35, issue.1, pp.83-90, 2004. ,
DOI : 10.1016/j.ijpara.2004.10.020
Review of the activation of TGF-?? in immunity, Journal of Leukocyte Biology, vol.85, issue.1, pp.29-33, 2009. ,
DOI : 10.1189/jlb.0708415
Integrative genome-wide analysis reveals a robust genomic glioblastoma signature associated with copy number driving changes in gene expression, 2009. ,
URL : https://hal.archives-ouvertes.fr/inserm-00352960
TGF-?? directly targets cytotoxic T cell functions during tumor evasion of immune surveillance, Cancer Cell, vol.8, issue.5, pp.369-380, 2005. ,
DOI : 10.1016/j.ccr.2005.10.012
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase, Nat. Med, vol.9, pp.1269-1274, 2003. ,
All in the head: obstacles for immune rejection of brain tumours, Immunology, vol.21, issue.1, pp.28-38, 2002. ,
DOI : 10.1016/S1471-4906(01)02031-2
Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back, J. Immunol, vol.158, pp.4521-4524, 1997. ,
The failure of current immunotherapy for malignant glioma, 1995. ,
Simultaneous measurement of serum tryptophan and kynurenine by HPLC, Clin. Chem, vol.43, pp.2424-2426, 1997. ,
A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape, J. Immunol, vol.168, pp.4772-4780, 2002. ,
B7-homolog 1 expression by human glioma: a new mechanism of immune evasion, NeuroReport, vol.16, issue.10, pp.1081-1085, 2005. ,
DOI : 10.1097/00001756-200507130-00010
Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis, Cancer Res, vol.63, pp.7462-7467, 2003. ,
Cell- and peptide-based immunotherapeutic approaches for glioma, Trends in Molecular Medicine, vol.14, issue.5, 2008. ,
DOI : 10.1016/j.molmed.2008.03.003
Vaccination of recurrent glioma patients with tumour lysatepulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial, Br. J. Cancer, vol.89, pp.1172-1179, 2003. ,
Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial, Clinical Cancer Research, vol.11, issue.11, pp.4160-4167, 2005. ,
DOI : 10.1158/1078-0432.CCR-05-0120
Vaccination with Tumor Lysate-Pulsed Dendritic Cells Elicits Antigen-Specific, Cytotoxic T-Cells in Patients with Malignant Glioma, Cancer Research, vol.64, issue.14, pp.4973-4979, 2004. ,
DOI : 10.1158/0008-5472.CAN-03-3505
Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics, Clin. Cancer Res, vol.13, pp.566-575, 2007. ,
ACKNOWLEDGMENTS We thank persons and organizations which have contributed to this work: Stéphane Moiteaux for his excellent technical assistance Catros and A. Clavreul for their kind gifts of the JEG-3 trophoblastic cell line, U251 and U87MG cell lines, respectively; the Biogenouest® transcriptomic platform from Rennes for the microarray analysis; Alain Feutrel and Pascale Bellaud from the Biogenouest® histopathology platform (IFR 140 ,